Clinical

Videos

“Ideally…we have a technology that's noninvasive that we can use in the clinic, where they don't require any anesthesia to…break the stones and make them smaller,” says Mathew D. Sorensen, MD, MS, FACS.

Dr. Sorensen discusses the potential of ultrasound stone treatment

Podcasts

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters 

 is compliance officer and medical director of coding and reimbursement, United Urology Group and Chesapeake Urology, in Towson, Maryland.

Mark Painter is CEO of PRS Urology SC in Denver.

Articles

"Each bill that is submitted for reimbursement must have a code for both the service performed and a reason for the service," writes Jonathan Rubenstein, MD, and Mark Painter.

How to bill for stone removal when stone is no longer present at time of procedure

Get ready for the 2021 AUA annual meeting with this preview of non-malignant topics.

AUA virtual meeting preview: BPH, stones, and incontinence

In this interview, Nicole L. Miller, MD, discusses her institution’s enhanced recovery after surgery protocol for ureteroscopy, which eliminates the use of opioids in patients undergoing this common procedure. 

Narcotics-free ureteroscopy: Anatomy of an ERAS protocol

Amy E. Krambeck, MD, discusses her recent trial comparing the efficacy of Trilogy and ShockPulse-SE lithotripters used in percutaneous nephrolithotomy.

Dr. Amy Krambeck discusses study comparing lithotripters for stone removal

“For harder, more aggressive stones, I'm more likely to use the Trilogy based on the results of the study. If I have a softer, easier stone, I prefer the lightness of the ShockPulse," said lead study investigator Amy E. Krambeck, MD.

Lithotripters Trilogy and ShockPulse-SE show efficacy for stones

The FDA approved lumasiran in November 2020 as the first drug for the treatment of patients with primary hyperoxaluria type 1.

Pivotal phase 3 trial of lumasiran in PH1 meets primary end point

Kyle Wood, MD, discusses the different types of hyperoxaluria, the urologist’s role in managing the condition, and the treatments for it.

Hyperoxaluria: What is the urologist’s role in diagnosis and treatment?

“While patient facing apps hold great potential to support self-management behaviors, particularly in stone disease, thoughtful consideration across an array of domains should really be taken prior to supporting or even recommending one of these apps to a patient,” says Jared S. Winoker, MD.

Kidney Stones